EP343: Triglycerides and Heart DIsease (Part 2)

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. Podcast Episode Summary Introduction Dr. Auric Bishop (also known as Warwick Bishop), a cardiologist, author, and CEO of the Healthy Heart Network, hosts this episode focused on managing elevated triglycerides. The episode is part two of a triglyceride series, diving into both lifestyle interventions and medical approaches to lowering triglycerides, which affect millions of Australians and contribute to preventable heart disease. Key Takeaways: Elevated triglycerides are markers of underlying metabolic dysfunction including insulin resistance, central weight gain, visceral fat, inflammation, and high blood pressure—creating a "nasty pack" of cardiovascular risk factors. Lifestyle management of triglycerides should be the first step and includes reducing saturated fats and refined sugars in the diet, since both can be converted to fatty acids and triglycerides. Exercise lowers triglycerides through two mechanisms: by improving insulin resistance and directly using triglycerides as fuel when energy expenditure increases. Alcohol significantly elevates triglycerides through enzymatic pathways that convert it to acetyl-CoA, a building block for fatty acid production, making alcohol reduction critical. The landmark GISSI-P trial demonstrated that one gram of fish oil daily reduced sudden cardiac death by 45% and overall mortality by 20% in post-heart attack patients, suggesting marine omega-3s are most beneficial for secondary prevention. Subsequent large trials (VITAL, ASCEND, ORIGIN) showed limited benefit of fish oil supplementation in primary prevention populations without prior cardiac events, indicating timing and patient selection are crucial. The REDUCE-IT trial demonstrated that icosapent ethyl (a pure EPA supplement) reduced major adverse cardiac events by approximately 20% in high-risk patients on statin therapy, suggesting the benefit may relate to anti-inflammatory effects rather than triglyceride reduction alone. The Physician's Health Study found that individuals in the highest quartile of omega-3 blood levels had a 90% relative risk reduction in cardiovascular events, with omega-3 index being a stronger predictor of sudden cardiac death than cholesterol or inflammation levels. EPA appears particularly cardioprotective, while DHA is more important for fetal brain and eye development, suggesting different roles for the two marine omega-3 fatty acids.